Combination therapy reduces transarterial chemoembolization resistance in advanced hepatocellular carcinoma.

IF 3.2 Q3 ONCOLOGY

World journal of clinical oncology Pub Date : 2025-08-24 DOI:10.5306/wjco.v16.i8.109419

Hu-Yu Jiao, Xin-Mei Yan, Jun-Xin Li, Zhen-Gang Zhang

{"title":"Combination therapy reduces transarterial chemoembolization resistance in advanced hepatocellular carcinoma.","authors":"Hu-Yu Jiao, Xin-Mei Yan, Jun-Xin Li, Zhen-Gang Zhang","doi":"10.5306/wjco.v16.i8.109419","DOIUrl":null,"url":null,"abstract":"Background: Transarterial chemoembolization (TACE) is a main treatment for advanced hepatocellular carcinoma (HCC), but tumors often become resistant. Combining TACE programmed cell death (ligand) 1 [PD-(L)1] inhibitors and molecular targeted therapies (MTT) may improve outcomes, but its role in preventing TACE resistance requires further investigation.Aim: To compare if TACE plus PD-(L)1 inhibitors and MTT reduces TACE resistance and improves survival in advanced HCC compared to TACE alone.Methods: We analyzed 721 patients: 532 received TACE only, and 72 received TACE with PD-(L)1 inhibitors and MTT. After matching patient characteristics, 144 patients (72 pairs) were compared. Tumor progression after 3 treatment cycles was measured.Results: The combination group exhibited significantly lower TACE resistance rates compared to the monotherapy group (9.7% vs 38.8%, P < 0.001). Moreover, patients in the combination group experienced prolonged progression-free survival (progression-free survival: 17.5 months vs 9.1 months, P = 0.004) and overall survival (overall survival: 20.8 months vs 16.4 months, P = 0.008). These findings underscore the efficacy of combination therapy in enhancing therapeutic outcomes in advanced HCC.Conclusion: Adding immunotherapy and targeted drugs to TACE significantly reduces treatment resistance and improves survival in advanced liver cancer, suggesting it may become a new standard treatment.","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 8","pages":"109419"},"PeriodicalIF":3.2000,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400234/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v16.i8.109419","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Transarterial chemoembolization (TACE) is a main treatment for advanced hepatocellular carcinoma (HCC), but tumors often become resistant. Combining TACE programmed cell death (ligand) 1 [PD-(L)1] inhibitors and molecular targeted therapies (MTT) may improve outcomes, but its role in preventing TACE resistance requires further investigation.

Aim: To compare if TACE plus PD-(L)1 inhibitors and MTT reduces TACE resistance and improves survival in advanced HCC compared to TACE alone.

Methods: We analyzed 721 patients: 532 received TACE only, and 72 received TACE with PD-(L)1 inhibitors and MTT. After matching patient characteristics, 144 patients (72 pairs) were compared. Tumor progression after 3 treatment cycles was measured.

Results: The combination group exhibited significantly lower TACE resistance rates compared to the monotherapy group (9.7% vs 38.8%, P < 0.001). Moreover, patients in the combination group experienced prolonged progression-free survival (progression-free survival: 17.5 months vs 9.1 months, P = 0.004) and overall survival (overall survival: 20.8 months vs 16.4 months, P = 0.008). These findings underscore the efficacy of combination therapy in enhancing therapeutic outcomes in advanced HCC.

Conclusion: Adding immunotherapy and targeted drugs to TACE significantly reduces treatment resistance and improves survival in advanced liver cancer, suggesting it may become a new standard treatment.

Abstract Image

查看原文本刊更多论文

联合治疗可降低晚期肝细胞癌经动脉化疗栓塞抵抗。

背景：经动脉化疗栓塞（TACE）是晚期肝细胞癌（HCC）的主要治疗方法，但肿瘤经常产生耐药性。联合TACE程序性细胞死亡（配体）1 [PD-(L)1]抑制剂和分子靶向治疗（MTT）可能改善预后，但其在预防TACE耐药中的作用有待进一步研究。目的：比较与单独使用TACE相比，TACE联合PD-(L)1抑制剂和MTT是否能降低晚期HCC患者的TACE耐药并提高生存率。方法：我们分析了721例患者：532例仅接受TACE治疗，72例接受TACE联合PD-(L)1抑制剂和MTT治疗。匹配患者特征后，对144例患者（72对）进行比较。观察3个治疗周期后肿瘤进展情况。结果：联合治疗组TACE耐药率明显低于单药治疗组（9.7% vs 38.8%, P < 0.001）。此外，联合组患者的无进展生存期（17.5个月vs 9.1个月，P = 0.004）和总生存期（20.8个月vs 16.4个月，P = 0.008）延长。这些发现强调了联合治疗在提高晚期HCC治疗效果方面的有效性。结论：TACE联合免疫治疗和靶向药物治疗可显著降低晚期肝癌的治疗耐药，提高生存率，有望成为新的标准治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World journal of clinical oncology ONCOLOGY-

自引率

0.00%

发文量

585

期刊介绍： The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.